Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovasculgen in Secondary Raynaud's Phenomenon and Systemic Scleroderma
NCT02356809Phase 2Unknown
- Sponsor
- Artgen Biotech
- Start
- Mar 2015
- Primary completion
- Mar 2015
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of neovasculgen in Raynaud's phenomenon (RP) and systemic sclerosis (SSc) (2 arms), sponsored by Artgen Biotech. Primary endpoints: Frequency of new digital ulcers at 180 days and Frequency of adverse events at 180 days. Status: unknown.
02
Drugs
neovasculgen
03
Conditions
Raynaud's phenomenon (RP)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02356809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356809.